Christopher Parker

Chris earned his B.S. in Chemistry from Case Western Reserve University, and his Ph.D. in Chemistry from Yale University, under the supervision of David A. Spiegel. During his graduate studies he developed a class of bifunctional molecules that recruit endogenous antibodies to specific targets, resulting in their immune-mediated clearance. He carried out postdoctoral studies under the supervision of Ben Cravatt as a fellow of the American Cancer Society at Scripps Research, where he developed new chemical proteomic methods for global ligand and target discovery. Chris started his independent lab at Scripps in August 2018, where he is now Professor in the Department of Chemistry. His group develops chemistry-centric strategies to investigate human biology in therapeutic contexts. Chris is recipient of the CDRMP New Investigator Idea Development Award from the DoD, the Exploratory Cell Network Award from the Chan Zuckerberg Initiative, and is co-founder of Belharra Therapeutics.